For: | Sobhani N, Generali D, Zanconati F, Bortul M, Scaggiante B. Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives? World J Clin Oncol 2018; 9(2): 26-32 [PMID: 29651384 DOI: 10.5306/wjco.v9.i2.26] |
---|---|
URL: | https://www.wjgnet.com/2218-4333/full/v9/i2/26.htm |
Number | Citing Articles |
1 |
Periklis Katopodis, Vladimir Anikin, Uday Kishore, Thomas Carter, Marcia Hall, Nizar Asadi, Andreas Polychronis, Emmanouil Karteris. Circulating tumour cells and circulating cell-free DNA in patients with lung cancer: a comparison between thoracotomy and video-assisted thoracoscopic surgery. BMJ Open Respiratory Research 2021; 8(1): e000917 doi: 10.1136/bmjresp-2021-000917
|
2 |
Xinglu Jiang, Chenggui Zhao, Xiaobo Fan, Wei Xu, Rui Zhang, Hongbo Xu, Guoqiu Wu. A DNA-modified hydrogel for simultaneous purification, concentration and detection of targeted cfDNA in human serum. RSC Advances 2019; 9(6): 3407 doi: 10.1039/C8RA10138H
|
3 |
Navid Sobhani, Marianna Sirico, Daniele Generali, Fabrizio Zanconati, Bruna Scaggiante. Circulating cell-free nucleic acids as prognostic and therapy predictive tools for metastatic castrate-resistant prostate cancer. World Journal of Clinical Oncology 2020; 11(7): 450-463 doi: 10.5306/wjco.v11.i7.450
|
4 |
Domenico Tierno, Gabriele Grassi, Fabrizio Zanconati, Marina Bortul, Bruna Scaggiante. An Overview of Circulating Cell-Free Nucleic Acids in Diagnosis and Prognosis of Triple-Negative Breast Cancer. International Journal of Molecular Sciences 2023; 24(2): 1799 doi: 10.3390/ijms24021799
|
5 |
Madhumathy G. Nair, Rakesh S. Ramesh, Chandrakala M. Naidu, Apoorva D. Mavatkar, Snijesh V. P., Vishakha Ramamurthy, Vidya M. Somashekaraiah, Anupama C. E., Kiruthiga Raghunathan, Anuradha Panigrahi, Manjula Das, Sujan K. Dhar, Jyothi S. Prabhu. Estimation of ALU Repetitive Elements in Plasma as a Cost-Effective Liquid Biopsy Tool for Disease Prognosis in Breast Cancer. Cancers 2023; 15(4): 1054 doi: 10.3390/cancers15041054
|
6 |
Ugur Gezer, Abel J. Bronkhorst, Stefan Holdenrieder. The Utility of Repetitive Cell-Free DNA in Cancer Liquid Biopsies. Diagnostics 2022; 12(6): 1363 doi: 10.3390/diagnostics12061363
|
7 |
Flavia Ultimescu, Ariana Hudita, Daniela Elena Popa, Maria Olinca, Horatiu Alin Muresean, Mihail Ceausu, Diana Iuliana Stanciu, Octav Ginghina, Bianca Galateanu. Impact of Molecular Profiling on Therapy Management in Breast Cancer. Journal of Clinical Medicine 2024; 13(17): 4995 doi: 10.3390/jcm13174995
|
8 |
Vincent Camus, Fabrice Jardin. Cell-free DNA and the Monitoring of Lymphoma Treatment. Pharmacogenomics 2019; 20(18): 1271 doi: 10.2217/pgs-2019-0099
|
9 |
Gabriella Cirmena, Martina Dameri, Francesco Ravera, Piero Fregatti, Alberto Ballestrero, Gabriele Zoppoli. Assessment of Circulating Nucleic Acids in Cancer: From Current Status to Future Perspectives and Potential Clinical Applications. Cancers 2021; 13(14): 3460 doi: 10.3390/cancers13143460
|
10 |
Mohammad Hadi Abbasian, Ali M. Ardekani, Navid Sobhani, Raheleh Roudi. The Role of Genomics and Proteomics in Lung Cancer Early Detection and Treatment. Cancers 2022; 14(20): 5144 doi: 10.3390/cancers14205144
|
11 |
Caterina Gianni, Michela Palleschi, Filippo Merloni, Giandomenico Di Menna, Marianna Sirico, Samanta Sarti, Alessandra Virga, Paola Ulivi, Lorenzo Cecconetto, Marita Mariotti, Ugo De Giorgi. Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer. International Journal of Molecular Sciences 2022; 23(22): 14197 doi: 10.3390/ijms232214197
|
12 |
Ying-Hsiu Su, Amy K. Kim, Surbhi Jain. Liquid biopsies for hepatocellular carcinoma. Translational Research 2018; 201: 84 doi: 10.1016/j.trsl.2018.07.001
|
13 |
Z. Basit, I. Gull, I. Tipu, Z. Abbas, M. M. Iqbal, M. S. Aslam. Quantitative Analysis of Plasma Circulating Cell-Free Nucleic Acid Based Biomarkers in Patients with Breast Cancer. Molecular Genetics, Microbiology and Virology 2021; 36(S1): S23 doi: 10.3103/S0891416821050050
|
14 |
Kajal Nandi, Rashmi Verma, Rajni Dawar, Binita Goswami. Cell free DNA: revolution in molecular diagnostics – the journey so far. Hormone Molecular Biology and Clinical Investigation 2020; 41(1) doi: 10.1515/hmbci-2019-0012
|
15 |
Evaluation of the cell-free DNA integrity index as a liquid biopsy marker to differentiate hepatocellular carcinoma from chronic liver disease. Frontiers in Molecular Biosciences 2022; 9 doi: 10.3389/fmolb.2022.1024193
|
16 |
Min Pan, Jiafeng Lu, Zhiyu Liu, Huajuan Shi, Yunfei Bai, Pingsheng Chen, Qinyu Ge. Integrity of cell‐free DNA in maternal plasma extracellular vesicles as a potential biomarker for non‐invasive prenatal testing. International Journal of Gynecology & Obstetrics 2022; 158(2): 406 doi: 10.1002/ijgo.13976
|
17 |
Richard Tancredi, Navid Sobhani, Martina Catalano, Giandomenico Roviello, Daniele Generali. Current Trends in Liquid Biopsy Tracking Resistance in Molecular Breast Cancer-Targeted Therapies. Genes 2025; 16(4): 443 doi: 10.3390/genes16040443
|
18 |
Geoffroy Poulet, Fanny Garlan, Sonia Garrigou, Eleonora Zonta, Leonor Benhaim, Marie-Jennifer Carrillon, Audrey Didelot, Delphine Le Corre, Claire Mulot, Philippe Nizard, Frederic Ginot, Audrey Boutonnet-Rodat, Helene Blons, Jean-Baptiste Bachet, Julien Taïeb, Aziz Zaanan, Vanna Geromel, Laurence Pellegrina, Pierre Laurent-Puig, Shu-Fang Wang-Renault, Valerie Taly. Characterization of Plasma Cell-Free DNA Integrity Using Droplet-Based Digital PCR: Toward the Development of Circulating Tumor DNA-Dedicated Assays. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.639675
|
19 |
Marina Bortul, Fabiola Giudici, Domenico Tierno, Daniele Generali, Serena Scomersi, Gabriele Grassi, Cristina Bottin, Maria Rosa Cappelletti, Fabrizio Zanconati, Bruna Scaggiante. A Case–Control Study by ddPCR of ALU 260/111 and LINE-1 266/97 Copy Number Ratio in Circulating Cell-Free DNA in Plasma Revealed LINE-1 266/97 as a Potential Biomarker for Early Breast Cancer Detection. International Journal of Molecular Sciences 2023; 24(10): 8520 doi: 10.3390/ijms24108520
|
20 |
Caterina Gianni, Michela Palleschi, Filippo Merloni, Sara Bleve, Chiara Casadei, Marianna Sirico, Giandomenico Di Menna, Samanta Sarti, Lorenzo Cecconetto, Marita Mariotti, Ugo De Giorgi. Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer. Cancers 2022; 15(1): 96 doi: 10.3390/cancers15010096
|
21 |
Gazi Nurun Nahar Sultana, Ferdowsi Akter, S. M. Hasan Israfil, Utpal Chandra Ray, Rumana Akther Jahan, Mohammad Shawkat Ali, Salim Al Din, Shafiqur Rahman, Rezaul Halim, Mohammad Sahajadul Alam. Quantitative analysis of serum cell-free DNA as a predictive and prognostic marker in breast cancer patients. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1171412
|
22 |
Jenna Morgan, Lynda Wyld. Management of Breast Cancer in Older Women. 2019; : 59 doi: 10.1007/978-3-030-11875-4_5
|
23 |
Camila Giro, Alayne M. T. D. Yamada, Felipe José S. M. Cruz, Lilian A. do R. Barros, Beatriz da C. A. Alves, Fernando L. A. Fonseca, Auro del Giglio. Measuring cfDNA integrity as a biomarker for predicting neoadjuvant chemotherapy response in breast cancer patients: a pilot study. Breast Cancer Research and Treatment 2024; 206(2): 329 doi: 10.1007/s10549-024-07366-y
|
24 |
Bridgette A Sisson, Jasmina Uvalic, Kevin Kelly, Pavalan Selvam, Andrew N Hesse, Guruprasad Ananda, Harshpreet Chandok, Daniel Bergeron, Lauren Holinka, Honey V Reddi. Technical and Regulatory Considerations for Taking Liquid Biopsy to the Clinic: Validation of the JAX PlasmaMonitorTM Assay. Biomarker Insights 2019; 14 doi: 10.1177/1177271919826545
|
25 |
Ludmila A. Alekseeva, Aleksandra V. Sen’kova, Marina A. Zenkova, Nadezhda L. Mironova. Targeting Circulating SINEs and LINEs with DNase I Provides Metastases Inhibition in Experimental Tumor Models. Molecular Therapy - Nucleic Acids 2020; 20: 50 doi: 10.1016/j.omtn.2020.01.035
|
26 |
Navid Sobhani, Alberto D’Angelo, Matteo Pittacolo, Giuseppina Mondani, Daniele Generali. Future AI Will Most Likely Predict Antibody-Drug Conjugate Response in Oncology: A Review and Expert Opinion. Cancers 2024; 16(17): 3089 doi: 10.3390/cancers16173089
|